Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Humacyte, Inc. - Common Stock (NQ:HUMA)

0.4101 -0.0599 (-12.74%)
Delayed Quote Updated: 10:27 AM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Humacyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Humacyte (HUMA) Q2 2026 Earnings Call Transcript ↗
Phase III trial shows 91 more catheter-free days for dialysis patients. 
Via The Motley Fool
Topics Earnings
News headline image
Humacyte Q2 Earnings Call Highlights ↗
Humacyte (NASDAQ:HUMA) reported second-quarter commercial sales growth while outlining plans to expand adoption of its SYMVESS vascular repair product, submit a supplemental biologics license... 
Via MarketBeat
Topics Earnings
Humacyte Inc (NASDAQ:HUMA) Reports Q4 Revenue Miss, Shares Drop Pre-Market ↗
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
News headline image
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $20.3 million. Humacyte (NASDAQ:HUMA) shares moved upwards by 5.45% to... 
Via Benzinga
News headline image
MultiBagger MicroCaps IGC, RCT, PBK, HUMA, PRSO Stocks to Watch Now
Via AB Newswire
Topics Artificial Intelligence
MissionIRNewsBreaks – Humacyte Inc. (NASDAQ: HUMA) Prices $50 Million Public Offering
Via Investor Brand Network
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
Get insights into the top gainers and losers of Wednesday's after-hours session. ↗
Via Chartmill
News headline image
Humacyte (HUMA) Q1 2025 Earnings Transcript ↗
Humacyte (HUMA) Q1 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Humacyte (HUMA) Q1 2026 Earnings Transcript ↗
Humacyte (HUMA) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Humacyte Q1 Earnings Call Highlights ↗
Humacyte (NASDAQ:HUMA) reported first-quarter 2026 Symvess sales of $0.5 million and outlined a series of commercial, clinical and cost-reduction initiatives aimed at accelerating adoption of its... 
Via MarketBeat
Topics Earnings
News headline image
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA
From Kahn Swick & Foti, LLC
Via Business Wire
The market is filled with gapping stocks in Monday's session. ↗
Via Chartmill
News headline image
HUMA Stock Just Shot Up 12% Today – Here’s Everything To Know About The DOD Funding Fueling The Surge ↗
The company stated that its product, Symvess, is the only human-derived bioengineered blood vessel approved by the U.S. Food and Drug Administration. 
Via Stocktwits
News headline image
Humacyte (HUMA) Q3 2025 Earnings Call Transcript ↗
Humacyte (HUMA) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Death Earnings
News headline image
Humacyte Inc (NASDAQ:HUMA) Beats on EPS but Misses on Revenue in Q3 ↗
Humacyte (HUMA) missed Q3 revenue estimates but delivered a smaller-than-expected loss per share. The stock rose as investors focused on its pipeline progress toward key regulatory milestones. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Insights Ahead: Humacyte's Quarterly Earnings ↗
 
Via Benzinga
BioMedNewsBreaks — Humacyte, Inc. (NASDAQ: HUMA) Announces $60 Million Registered Direct Offering of Common Stock and Warrants
Via Investor Brand Network
News headline image
D. Boral Capital Acted as Exclusive Placement Agent to Humacyte (Nasdaq: HUMA) in Connection with its $60,000,000 Registered Direct Offering
Via ACCESS Newswire
News headline image
Top stock movements in today's session. ↗
Intrigued by the market activity one hour before the close of the markets on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are moving on Tuesday? ↗
Curious about what's happening in today's session? Check out the latest stock movements and price changes. 
Via Chartmill
News headline image
Tuesday's session: gap up and gap down stocks ↗
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Russell 2000 Hits All-Time Highs: 8 Stocks Power Small-Cap Comeback ↗
Small-cap benchmark Russell 2000 ETF hits record high after Fed cuts rates, hinting at more cuts. Small caps rally 43% since tariff-driven selloff. 
Via Benzinga
Topics ETFs Economy
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.